Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 26:24:454-478.
doi: 10.17179/excli2025-8285. eCollection 2025.

Coronary microvascular dysfunction: pathophysiology, diagnosis, and therapeutic strategies across cardiovascular diseases

Vincenzo Scarica  1 , Riccardo Rinaldi  1   2 , Francesco Maria Animati  1 , Matteo Manzato  1 , Rocco A Montone  1   3
Affiliations
Review

Coronary microvascular dysfunction: pathophysiology, diagnosis, and therapeutic strategies across cardiovascular diseases

Vincenzo Scarica et al. EXCLI J. .

Abstract

Ischemic heart disease (IHD) is a leading cause of morbidity and mortality worldwide, presenting with acute and chronic coronary syndromes. Although coronary atherosclerosis is a major cause of IHD, many patients with angina or myocardial ischemia do not have obstructive coronary heart disease and impairment of the coronary microcirculation has been increasingly implicated as a relevant cause of IHD. Therefore, coronary microvascular dysfunction (CMD) refers to a term covering a wide spectrum of structural and functional alterations which affect the coronary microcirculation leading to myocardial ischemia and angina. The advent of non-invasive and invasive functional tests has exponentially broadened the ability to recognize CMD and delineate related clinical and biochemical features. Despite major advances in diagnosing and stratifying this condition, therapeutic strategies remain limited and poorly defined. In this review, we will provide an overview of the pathophysiology and the diagnostic evaluation of CMD across the spectrum of cardiovascular diseases. Furthermore, we will discuss the novel therapeutic strategies available for these patients in the perspective of a personalized medicine approach.

Keywords: ANOCA; INOCA; coronary microvascular dysfunction; coronary spasm; precision medicine.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Table 1
Table 1. Non-invasive techniques for the diagnosis of CMD
Table 2
Table 2. Current therapeutic strategies for microvascular dysfunction
Figure 1
Figure 1. Pathophysiology of coronary microvascular dysfunction
(Abbreviations: CMD: coronary microvascular dysfunction; VSMC: vascular smooth muscle cells)
Figure 2
Figure 2. Molecular pathways involved in coronary microvascular dysfunction
Abbreviations. AP-1: Activator Protein 1; ERK1/2: Extracellular Signal-Regulated Kinases 1 and 2; ET1: Endothelin 1; HIF-1: Hypoxia-Inducible Factor 1; JNK: c-Jun N-terminal Kinase; MAPK: Mitogen-Activated Protein Kinase; NF-κB: Nuclear Factor Kappa B; NO: Nitric Oxide; NOS: Nitric Oxide Synthase; NOX: NADPH Oxidase; ONOO⁻: Peroxynitrite; p38MAPK: p38 Mitogen-Activated Protein Kinase; p66shc: SHC Adaptor Protein 1; Rho Kinase: Rho-Associated Protein Kinase; RhoA: Ras Homolog Family Member A; ROS: Reactive Oxygen Species; SIRT1: Sirtuin 1; XO: Xanthine Oxidase; XDH: Xanthine Dehydrogenase.
Figure 3
Figure 3. Epigenetic modifications involved in coronary microvascular dysfunction
Abbreviations. TNFα: Tumor necrosis factor; VSMC: vascular smooth muscle cells
Figure 4
Figure 4. The role of CMD across cardiovascular diseases
Abbreviations. CAD: coronary artery disease; HFpEF: Heart failure with preserved ejection fraction; MINOCA: myocardial infarction and non-obstructive coronary arteries; MVA: microvascular angina; MVO: microvascular obstruction.
See this image and copyright information in PMC

References

    1. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38:143–153. doi: 10.1093/eurheartj/ehw149. Available from: http://dx.doi.org/10.1093/eurheartj/ehw149. - DOI - DOI - PubMed
    1. Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO, Higano ST, Holmes DR, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131:838–841. doi: 10.7326/0003-4819-131-11-199912070-00007. Available from: http://dx.doi.org/10.7326/0003-4819-131-11-199912070-00007. - DOI - DOI - PubMed
    1. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. doi: 10.1016/S0140-6736(17)32714-9. Available from: http://dx.doi.org/10.1016/S0140-6736(17)32714-9. - DOI - DOI - PubMed
    1. Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016;37:1504–1513. doi: 10.1093/eurheartj/ehv647. Available from: http://dx.doi.org/10.1093/eurheartj/ehv647. - DOI - DOI - PMC - PubMed
    1. Ben-Yehuda O, Kazi DS, Bonafede M, Wade SW, Machacz SF, Stephens LA, et al. Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payer database. Catheter Cardiovasc Interv. 2016;88:1017–1024. doi: 10.1002/ccd.26365. Available from: http://dx.doi.org/10.1002/ccd.26365. - DOI - DOI - PubMed

LinkOut - more resources